Halozyme CEO sells 60,000 shares near $100
HALOZYME THERAPEUTICS, INC.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
HALOZYME THERAPEUTICS, INC. (HALO) reported that President and CEO Helen Torley exercised stock options and sold common shares under a pre-arranged Rule 10b5-1 trading plan. Over August 17–19, 2026, she exercised options for 60,000 shares at $18.41 per share and sold 60,000 common shares in multiple open-market transactions at weighted-average prices generally between the high $90s and about $108 per share. The options exercised were part of a ten-year grant originally awarded in February 2018 and expiring in February 2028.
Insider Trade Summary 10b5-1
Exercise and Sale: 60,000 shares ($5.17M approx. pre-tax spread)
Exercise and Sale
17 txns
Insider
Torley Helen
Role
PRESIDENT AND CEO
Sold
60,000 shs ($6.28M)
Approx. gross sale proceeds
$6.28M
Approx. exercise cost
$1.10M
Approx. pre-tax spread
$5.17M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Option to Purchase Common Stock F1, F13 | 20,000 | $18.41 | $368K |
| Exercise | Common Stock F1 | 20,000 | $18.41 | $368K |
| Sale | Common Stock F1, F10 | 7,200 | $106.358 | $766K |
| Sale | Common Stock F1, F11 | 9,600 | $107.224 | $1.03M |
| Sale | Common Stock F1, F12 | 3,200 | $107.765 | $345K |
| Exercise | Option to Purchase Common Stock F1, F13 | 20,000 | $18.41 | $368K |
| Exercise | Common Stock F1 | 20,000 | $18.41 | $368K |
| Sale | Common Stock F1, F7 | 5,703 | $103.083 | $588K |
| Sale | Common Stock F1, F8 | 4,897 | $104.11 | $510K |
| Sale | Common Stock F1, F9 | 9,400 | $104.874 | $986K |
| Exercise | Option to Purchase Common Stock F1, F13 | 20,000 | $18.41 | $368K |
| Exercise | Common Stock F1 | 20,000 | $18.41 | $368K |
| Sale | Common Stock F1, F2 | 900 | $98.958 | $89K |
| Sale | Common Stock F1, F3 | 500 | $100.457 | $50K |
| Sale | Common Stock F1, F4 | 2,100 | $101.766 | $214K |
| Sale | Common Stock F1, F5 | 9,000 | $102.553 | $923K |
| Sale | Common Stock F1, F6 | 7,500 | $103.482 | $776K |
Holdings After Transaction:
Option to Purchase Common Stock — 141,552 contracts (Direct);
Common Stock — 767,780 shares (Direct)
Footnotes (13)
- F1. The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028.
- F2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $98.580 to $99.210. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3. Represents a weighted average sales price per share. The shares were sold at prices ranging from $99.980 to $100.780. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F4. Represents a weighted average sales price per share. The shares were sold at prices ranging from $101.140 to $102.120. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F5. Represents a weighted average sales price per share. The shares were sold at prices ranging from $102.140 to $103.050. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F6. Represents a weighted average sales price per share. The shares were sold at prices ranging from $103.160 to $104.010. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F7. Represents a weighted average sales price per share. The shares were sold at prices ranging from $102.550 to $103.540. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F8. Represents a weighted average sales price per share. The shares were sold at prices ranging from $103.570 to $104.550. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F9. Represents a weighted average sales price per share. The shares were sold at prices ranging from $104.585 to $105.080 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F10. Represents a weighted average sales price per share. The shares were sold at prices ranging from $105.69 to $106.680 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F11. Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.69 to $107.680 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F12. Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.69 to $107.900 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F13. Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 14, 2018.
Key Figures
Options exercised: 60,000 shares
Shares sold: 60,000 shares
Option exercise price: $18.41 per share
+5 more
8 metrics
Options exercised
60,000 shares
Total option shares exercised by Helen Torley over August 17–19, 2026
Shares sold
60,000 shares
Total HALO common shares sold over August 17–19, 2026
Option exercise price
$18.41 per share
Exercise price for options converted into common stock
Sale price example
$98.958 per share
One reported weighted-average sales price on August 17, 2026
Highest reported weighted-average sale
$107.765 per share
Weighted-average sales price for a tranche on August 19, 2026
10b5-1 plan adoption date
December 3, 2025
Date Helen Torley adopted the Rule 10b5-1 trading plan
Option grant date
February 14, 2018
Original grant date of the exercised options
Option expiration
February 2028
Stated expiration timing for the ten-year option grant
Key Terms
Rule 10b5-1, weighted average sales price per share, Exercise or conversion of derivative security, derivative security
4 terms
Rule 10b5-1 regulatory
"were made pursuant to a written trading plan adopted by the Reporting Person"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
Exercise or conversion of derivative security financial
"transaction_code_description":"Exercise or conversion of derivative security"
derivative security financial
"transaction_type":"derivative","transaction_shares":"20000.0000""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did HALO (HALOZYME THERAPEUTICS, INC.) report for Helen Torley?
HALO reported that CEO Helen Torley exercised 60,000 options and sold 60,000 common shares over August 17–19, 2026. The activity combined option exercises at $18.41 with multiple open-market sales at higher weighted-average prices.
How many HALO (HALOZYME) options did Helen Torley exercise and at what strike price?
Torley exercised options covering a total of 60,000 shares of HALO common stock. Each exercise involved an option with an exercise price of $18.41 per share, converting into an equal number of common shares before subsequent sales.
Were Helen Torley’s HALO (HALOZYME) trades made under a Rule 10b5-1 plan?
Yes. The company reports that the option exercises and related sales were made under a written Rule 10b5-1 trading plan adopted on December 3, 2025. This indicates the transactions were pre-arranged rather than timed opportunistically.
What is the origin and term of the options Helen Torley exercised in HALO stock?
The options Torley exercised were granted on February 14, 2018 and have a ten-year term expiring in February 2028. They vest over four years, with 25% after 12 months and the remainder in equal monthly installments thereafter.
AI-generated analysis. How Rhea-AI works. Not financial advice.
